https://doi.org/10.55788/15f5e10d
Currently, there are no FDA-approved therapies for the treatment of HHT and no adequately powered randomised controlled trials testing systemic therapies have been conducted in this population. To tackle this problem, the phase 2 PATH-HHT trial (NCT03910244) randomised 144 participants with HHT 2:1 to pomalidomide, 4 mg/day, or placebo. After 24 weeks of treatment, Prof. Keith McCrae (Cleveland Clinic, OH, USA) and colleagues analysed the change in the epistaxis severity score from baseline [1].
After 24 weeks of treatment, the drop in epistaxis severity score was significantly larger in participants treated with pomalidomide than placebo controls (difference -0.95; 95% CI -1.58 to -0.32; P=0.003; see Figure). HHT-QoL mean score changes from baseline favoured the experimental arm over the placebo arm (difference -1.4; 95% CI -2.6 to -0.3; P=0.015).
Figure: Epistaxis severity score change over time from baseline [1]
PT, post-treatment.
Neutropenia was more frequently observed in participants on pomalidomide (45% vs 10%; P<0.001) However, these cases were manageable by dose reductions, which did not appear to affect the efficacy of the treatment. Rash (36%) and constipation/diarrhoea (60%) were other common side effects in the pomalidomide arm. A tremor was observed in 8 participants in the experimental arm. “We will further investigate whether these cases were related to treatment,” stressed Prof. McCrae.
Overall, in the first adequately powered randomised clinical trial in HHT, pomalidomide was associated with decreased epistaxis severity scores and improvements in quality of life.
- McCrae K, et al. PATH-HHT, a double-blind, randomized, placebo-controlled trial in hereditary hemorrhagic telangiectasia demonstrates that pomalidomide reduces epistaxis and improves quality of life. Abstract LBA-3, 65th ASH Annual Meeting, 9–12 December 2023, San Diego, CA, USA.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Ancestry-specific study into CH delivers new leads Next Article
Axatilimab may present a new therapeutic strategy in chronic GvHD »
« Ancestry-specific study into CH delivers new leads Next Article
Axatilimab may present a new therapeutic strategy in chronic GvHD »
Table of Contents: ASH 2023
Featured articles
Meet the Trialist: Prof. Jeff Sharman on ELEVATE-TN
Leukaemia
FLT3-ITD-specific MRD assessment useful for clinical management of AML
MRD status rather than FLT3-ITD co-mutation is linked to the benefit of CR1-allo in NPM1-mutated AML
Promising results for quizartinib, venetoclax, and decitabine in FLT3-ITD mutated AML
AUGMENT-101: Excellent results for revumenib in R/R KMT2Ar leukaemia
Blinatumomab reduces toxicity in the consolidation phase in paediatric high-risk B-cell ALL
Promising results for olverembatinib in combination with venetoclax for Ph+ ALL
Undetectable MRD on maintenance venetoclax, acalabrutinib, and obinutuzumab in the majority of R/R CLL participants
Lymphoma
Is allogeneic stem cell transplantation a solid option in R/R LBCL or R/R T-cell lymphoma?
Encouraging results for the addition of acalabrutinib to lenalidomide and rituximab in follicular lymphoma
Can ibrutinib ameliorate outcomes in R/R ABC-DLBCL undergoing autoSCT?
Primary phase 2 efficacy and safety results of M-Pola in relapsed/refractory LBCL
SYMPATICO: Ibrutinib plus venetoclax boosts PFS in R/R mantle cell lymphoma
Multiple Myeloma
KdD outperforms Kd in R/R MM also in participants with poor renal function
IsKia: Novel treatment regimen for MM delivers high MRD-negativity rates
Novel standard-of-care in newly diagnosed MM
Myeloproliferative Neoplasms
TRANSFORM-1: High spleen volume reduction rates for navitoclax plus ruxolitinib in myelofibrosis
Momelotinib beats controls regarding transfusion outcomes in myelofibrosis
DALIAH: Peginterferon-α head-to-head against hydroxyurea in MPN
Non-Malignant Haematology
Long-term efficacy and safety of iptacopan in PNH with anaemia
ADVANCE IV: Swift responses on efgartigimod in ITP
Favourable QoL and bleeding outcomes for rilzabrutinib in ITP
Novel risk assessment model acts on increasing hospital-acquired venous thromboembolism rates among children
Miscellaneous Topics
Axatilimab may present a new therapeutic strategy in chronic GvHD
Pomalidomide may become the first approved therapy for hereditary haemorrhagic telangiectasia
Ancestry-specific study into CH delivers new leads
Featured Interviews
Interview: Sandwich treatment model shows promise for mantle cell lymphoma
Meet the Trialist: Prof. Jeff Sharman on ELEVATE-TN
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy